Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to staphylococcus aureus and other gram-positive bacteria. Its product candidates include TD-1792 that has completed Phase III clinical trials for the treatment of skin and soft tissues infections; Revefenacin (TD-4208), a long-acting muscarinic antagonist, which has completed Phase III clinical studies for chronic obstructive pulmonary disease (COPD); and Velusetrag (TD-5108), an oral and investigational medicine that has completed Phase IIb studies for gastrointestinal motility disorders. The company's product candidates also comprise TD-8954, a selective 5-HT4 receptor agonist for treating gastrointestinal motility disorders; TD-1473, a pan-Janus kinase inhibitor, which has completed Phase Ib clinical study for ulcerative colitis; TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor that has completed Phase II study for neurogenic orthostatic hypotension; and TD-0714 and TD-1439 Neprilysin inhibitors, which have completed Phase I clinical studies for heart failure and chronic kidney disease. In addition, it focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium bromide, and vilanterol for the treatment of COPD and asthma; the inhaled bifunctional muscarinic antagonist-beta2 agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-808-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$60.37 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions
What is Theravance Biopharma's stock symbol?
Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."
How were Theravance Biopharma's earnings last quarter?
Theravance Biopharma Inc (NASDAQ:TBPH) announced its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($1.22) EPS for the quarter, beating analysts' consensus estimates of ($1.26) by $0.04. The biopharmaceutical company earned $8.32 million during the quarter, compared to analysts' expectations of $5.74 million. Theravance Biopharma had a negative net margin of 357.01% and a negative return on equity of 2,632.27%. View Theravance Biopharma's Earnings History.
When is Theravance Biopharma's next earnings date?
What price target have analysts set for TBPH?
4 analysts have issued 1 year target prices for Theravance Biopharma's stock. Their forecasts range from $38.00 to $55.00. On average, they anticipate Theravance Biopharma's share price to reach $47.00 in the next twelve months. This suggests a possible upside of 106.0% from the stock's current price. View Analyst Price Targets for Theravance Biopharma.
What is the consensus analysts' recommendation for Theravance Biopharma?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Theravance Biopharma.
What are Wall Street analysts saying about Theravance Biopharma stock?
Here are some recent quotes from research analysts about Theravance Biopharma stock:
- 1. According to Zacks Investment Research, "Theravance reported narrower-than-expected loss in Q4. Also, revenues beat estimates. The company received a huge boost when the FDA approved Yupelri, the first once daily nebulized LAMA option for COPD, in November. Formal launch activities of Yupelri are currently underway. Meanwhile, the agreement to divest its only marketed drug, Vibativ, will enable Theravance to focus solely on the launch efforts of Yupelri. Moreover, its pipeline programs target highly competitive therapeutic areas. The company's collaboration agreements are a consistent source of funds. However, any agreement termination might be a huge setback for the company as was the case in the past. Shares of the company have underperformed the industry so far this year." (3/13/2019)
- 2. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution, we are reiterating our OW rating and 12-month PT of $55 for TBPH shares. We believe the Street is underestimating the peak sales potential of TBPH’s key pipeline drugs. We think the commercialization of these programs could drive upward earnings revisions to levels not reflected in consensus expectations. Over time, TBPH expects to forward integrate from a royalty model to profit sharing and, ultimately, to building its own commercial infrastructure." (2/26/2019)
- 3. Needham & Company LLC analysts commented, "Theravance provided a 2Q18 corporate update today and announced top-line results from the Phase 2 trial of Hypotension (NOH). An impact on both blood pressure and symptoms is apparent and mgmt announced plans to start a Phase 3 trial around YE18. Separately, Phase 2 trial of Colitis (UC) has also been completed. As a reminder, 80mg data had previously been disclosed. Mgmt noted that a dose-response across 20mg-80mg-270mg is evident and that full data will be presented later this yr. Initiation of larger and longer-term trials in UC and Crohns Disease are planned for 2H18. We continue to expect Yupelri (revefenacin) FDA approval in COPD by 11/13/18 PDUFA date. Reiterate BUY. Pipeline is diverse, but Theravance is making noteworthy progress w/ several programs." (8/1/2018)
Has Theravance Biopharma been receiving favorable news coverage?
News headlines about TBPH stock have trended positive on Friday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Theravance Biopharma earned a daily sentiment score of 2.2 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.
Who are some of Theravance Biopharma's key competitors?
Some companies that are related to Theravance Biopharma include United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), GW Pharmaceuticals PLC- (GWPH), Ascendis Pharma A/S (ASND), Array Biopharma (ARRY), FibroGen (FGEN), Horizon Pharma (HZNP), Amneal Pharmaceuticals (AMRX), Taro Pharmaceutical Industries (TARO), TESARO (TSRO), HUTCHISON CHINA/S (HCM), ACADIA Pharmaceuticals (ACAD), Agios Pharmaceuticals (AGIO), Blueprint Medicines (BPMC) and Evotec (EVTCY).
What other stocks do shareholders of Theravance Biopharma own?
Who are Theravance Biopharma's key executives?
Theravance Biopharma's management team includes the folowing people:
- Mr. Rick E. Winningham, Chairman & CEO (Age 59)
- Mr. Bradford J. Shafer, Exec. VP, Gen. Counsel & Sec. (Age 59)
- Dr. Shehnaaz Suliman M.D., M.Phil., M.B.A., Sr. VP of Corp. Devel. & Strategy (Age 46)
- Mr. Frank Pasqualone, Sr. VP & Global Head of Acute Care Bus. (Age 63)
- Mr. Vijay Sabesan, VP of Technical Operations
Who are Theravance Biopharma's major shareholders?
Theravance Biopharma's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.97%), Norges Bank (1.58%), Northern Trust Corp (0.99%), Geode Capital Management LLC (0.90%), Geode Capital Management LLC (0.90%) and Chescapmanager LLC (0.75%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Burton G Malkiel, Frank Pasqualone, Henrietta Fore, Philip D Worboys, Renee D Gala, Rick E Winningham and Sharathchandra S Hegde. View Institutional Ownership Trends for Theravance Biopharma.
Which major investors are selling Theravance Biopharma stock?
TBPH stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Ibex Investors LLC, Virtus ETF Advisers LLC, Principal Financial Group Inc., California Public Employees Retirement System, NJ State Employees Deferred Compensation Plan, New York State Common Retirement Fund and Old West Investment Management LLC. Company insiders that have sold Theravance Biopharma company stock in the last year include Bradford J Shafer, Philip D Worboys, Renee D Gala and Sharathchandra S Hegde. View Insider Buying and Selling for Theravance Biopharma.
Which major investors are buying Theravance Biopharma stock?
TBPH stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, First Trust Advisors LP, Chicago Equity Partners LLC, Geode Capital Management LLC, Geode Capital Management LLC, BlackRock Inc., Candriam Luxembourg S.C.A. and D. E. Shaw & Co. Inc.. Company insiders that have bought Theravance Biopharma stock in the last two years include Burton G Malkiel, Frank Pasqualone, Henrietta Fore and Rick E Winningham. View Insider Buying and Selling for Theravance Biopharma.
How do I buy shares of Theravance Biopharma?
Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Theravance Biopharma's stock price today?
One share of TBPH stock can currently be purchased for approximately $22.82.
How big of a company is Theravance Biopharma?
Theravance Biopharma has a market capitalization of $1.27 billion and generates $60.37 million in revenue each year. The biopharmaceutical company earns $-215,520,000.00 in net income (profit) each year or ($3.99) on an earnings per share basis.
What is Theravance Biopharma's official website?
How can I contact Theravance Biopharma?
Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected]
MarketBeat Community Rating for Theravance Biopharma (NASDAQ TBPH)
MarketBeat's community ratings are surveys of what our community members think about Theravance Biopharma and other stocks. Vote "Outperform" if you believe TBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
